NCT04975971

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: Nicole Fram M.D. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery

Detailed description

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert, placed within the lower or upper eye lid canaliculus in conjunction with topical steroid Prior to or Following Corneal transplant or Cataract surgery

Conditions

• Anterior Chamber Inflammation
• Ocular Pain
• Corneal Edema
• Corneal Defect
• Penetrating KeratoPlasty
• Nuclear Cataract
• Cortical Cataract
• Cataract Senile

Interventions

Type	Name	Description
DRUG	Dextenza 0.4Mg Ophthalmic Insert	DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Timeline

• Start date: 2021-03-09
• Primary completion: 2021-05-19
• Completion: 2021-05-19
• First posted: 2021-07-26
• Last updated: 2021-07-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study